Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In May, the American Society of Clinical Oncology released guidelines on the use of germline genetic testing panels in concert with tumor testing for cancer patients.1 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Rebecca Sutphen, MD
Co-founder, chief medical officer, InformedDNA
Table of Contents

YOU MAY BE INTERESTED IN

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 
There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
Rebecca Sutphen, MD
Co-founder, chief medical officer, InformedDNA

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login